**Core tip:** Recent literature reports influences of microbiome alterations contributing to carcinogenesis of pancreatic cancer. The poor prognostics of pancreatic cancer are related to late recognition and treatment resistance, thus warranting investigations for modifiable risk factors, early screening biomarkers, and microenvironment elements that affect outcomes. Learning the role of microbiome in carcinogenesis may lead to identifying reliable, non-invasive screening strategies, and additional modifiable risk factors. Microbiome studies in pancreatic cancer could offer therapeutic targets and an extraordinary opportunity to favorably transform cancer response to existing treatment protocols and improve survival by reduction of cancer-related cachexia by manipulating human gut microbiota.

INTRODUCTION
============

A commensal microbiome, by definition maintains a symbiotic relationship in healthy individuals, offering protection from disease by nutritive, inflammatory-modulating activity, hormonal homeostasis, detoxification, and metabolic effects of bacterial metabolites\[[@B1]-[@B3]\]. Dysbiosis is the manifestation of a corrupt, imbalanced microbiome, which contributes to pathogenesis of several diseased states\[[@B2]\]. Recently, there are literature reports on influences of microbiome alteration contributing to carcinogenesis of multiple malignancies\[[@B1],[@B2],[@B4]-[@B6]\]. A classic pathogen in the literature is *Helicobacter pylori* (*H. pylori*), which has revealed inconsistent and paradoxical associations pending the body site studied\[[@B7],[@B8]\]. *H. pylori* has been extensively scrutinized as a risk factor for development of pancreatic cancer and an association is controversial\[[@B9]-[@B12]\]. Pancreatic cancer often denotes a poor clinical prognosis in part due to late recognition and treatment resistance, warranting investigations for modifiable risk factors, early screening biomarkers, and microenvironment elements that affect outcomes\[[@B13],[@B14]\].

MATERIALS AND METHODS
=====================

Search methods: PubMed, MEDLINE, and Web of Science for medical search terms: "pancreatic cancer" and "microbiome," "carcinogenesis," antibiotic," "probiotic," "microorganism," "bacteria," "colonization," "cachexia," or "infection." The relevant articles reference lists were also searched manually for additional articles. The last search was performed in October 2016.

Selection criteria: Manuscripts and abstracts describing pre-clinical studies, animal models, epidemiological studies, case series, case-control, retrospective chart reviews, prospective studies, pilot, meta-analysis, and literature topic reviews were included. There were no randomized clinical trials identified from these search terms. Articles were limited to abstract and manuscript publications in the English written language.

RESULTS
=======

Characterization of the healthy microbiome spectrum is ongoing. In 2012, the NIH Human Microbiome Project\[[@B3]\], demonstrated no microbial taxa were universally present across all humans in a single body site. The oral cavity contains an extensive reservoir of bacteria with more than 700 species observed, most of which have not been cultured in a laboratory\[[@B15],[@B16]\]. Healthy oral habitats are dominated by Streptococcus, followed by Haemophilus in the buccal mucosa, Actinomyces in the supragingival plaque, and Prevotella in adjacent, low-oxygen subgingival region\[[@B3]\].

Oral microbiome and pancreatic cancer
-------------------------------------

Alterations in the ecological balance of the microbiome exist during diseased oral cavity states including gingivitis and periodontal disease compared to a healthy oral cavity\[[@B16]-[@B20]\]. Periodontal disease, manifested by an inflamed oral activity, pathogenic oral flora, and tooth loss are well-established independent risk factors associated with development of pancreatic cancer\[[@B21]-[@B23]\]. Therefore, the shifts in taxa dominance and diversity of bacterial communities that deviate from an established healthy microbiome may be reflective of disease states\[[@B2],[@B3]\]. Pilot studies have proposed a role in oral pathogenic bacteria in periodontal disease as an early screening test and as a biomarker of pancreatic cancer\[[@B12],[@B24],[@B25]\]. Several dedicated studies have aimed to define microbiome changes in the oral cavity associated with pancreatic cancer, results are summarized in Table [1](#T1){ref-type="table"}.

###### 

Oral microbiome and pancreatic cancer

  **Ref**.                                             **Study design**                                                               **Case No**.                                                                             **Control No**.   **Detection**                   **Bacteria association**                                       **Outcome**                                                                                        **Author conclusion**
  ---------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ----------------- ------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Michaud et al\[[@B18]\], 2013, Western Europe        Prospective                                                                    405                                                                                      416               Plasma IgG                      *Porphyromonas gingivalis* ATTC 53978                          High titer *P. gingivalis* (IgG \> 200 ng/mL)                                                      Two fold increase in pancreatic cancer among individuals with high titer *P. gingivalis*
                                                       OR 2.14                                                                                                                                                                                                                                                                                                                                                                                     
                                                       *P* = 0.05                                                                                                                                                                                                                                                                                                                                                                                  
  High titer, *commensal* bacteria                     OR = 0.55                                                                      45% lower risk of pancreatic cancer compared to individuals with lower antibody levels                                                                                                                                                                                                                       
  95%CI: 0.36-0.83                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Farrell et al\[[@B12]\], 2012, United States         Case-control                                                                   28                                                                                       28                Salivary qPCR, Microarray       *Neisseria elongata* and *Streptococcus mitis*                 *N. elongata* and *S. mitis* significantly decreased                                               *N. elongate* and *S. mitis* combination ROC plot AUC 0.90 serves as 96% sensitive, 82% specific biomarker for pancreatic ca *vs*. healthy subjects
  ROC-plot AUC 0.90;                                                                                                                                                                                                                                                                                                                                                                                                                               
  95%CI: 0.78-0.96, *P* \< 0.0001                                                                                                                                                                                                                                                                                                                                                                                                                  
  *Granulicatella adiacens*                            *G. adiacens*                                                                                                                                                                                                                                                                                                                                                                               
  Significantly elevated compared to healthy control                                                                                                                                                                                                                                                                                                                                                                                               
  Lin et al\[[@B24]\], 2013, United States             Pilot                                                                          13                                                                                       12                Salivary rRNA                   *Bacteroides genus*                                            More common pancreatic cancer patient *vs* healthy subjects                                        Oral flora alterations in microbiome in pancreatic cancer exist compared to healthy individuals
  *P* = 0.002                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Corynebacterium* genus *Aggregatibacter* genus      Less common in pancreatic cancer *vs* healthy subjects *P* = 0.033 and 0.019                                                                                                                                                                                                                                                                                                                
  Torres et al\[[@B25]\], 2015 United States           Cross-sectional                                                                8                                                                                        22                Salivary rRNA, PCR              Higher *Leptotrichia* and lower *Porphyromonas* colonization   *Lepotrichia:Porphyromonas* ratio elevated in pancreatic cancer *vs* healthy control *P* = 0.001   L:P ratio may be reliable biomarker for pancreatic cancer diagnosis
  Fan et al\[[@B26]\], 2016 United States              Nested Case control                                                            361                                                                                      371               Salivary rRNA gene sequencing   Oral pathogens                                                 *P. gingivalis*                                                                                    Presence of oral pathogens are related to subsequent increased risk of pancreatic cancer. On contrary, *Fusobacteria* and *Leptotrichia* are associated with dose or concentration dependent decrease risk of pancreatic cancer
  *P. gingivalis*,                                     AOR = 1.60                                                                                                                                                                                                                                                                                                                                                                                  
  *A. actinomycetemcomitans*                           (95%CI: 1.15-2.22)                                                                                                                                                                                                                                                                                                                                                                          
                                                       *A. actinomycetes*                                                                                                                                                                                                                                                                                                                                                                          
                                                       OR = 2.20                                                                                                                                                                                                                                                                                                                                                                                   
                                                       (95%CI: 1.16-4.18)                                                                                                                                                                                                                                                                                                                                                                          
  *Fusobacteria* and *Leptotrichia*                    *Fusobacteria*                                                                                                                                                                                                                                                                                                                                                                              
  decreased risk                                                                                                                                                                                                                                                                                                                                                                                                                                   
  OR per percent increase of relative                                                                                                                                                                                                                                                                                                                                                                                                              
  Abundance                                                                                                                                                                                                                                                                                                                                                                                                                                        
  OR = 0.94                                                                                                                                                                                                                                                                                                                                                                                                                                        
  (95%CI: 0.89-0.99)                                                                                                                                                                                                                                                                                                                                                                                                                               
  *Lepotrichia*                                                                                                                                                                                                                                                                                                                                                                                                                                    
  OR = 0.87                                                                                                                                                                                                                                                                                                                                                                                                                                        
  (95%CI: 0.79-0.95)                                                                                                                                                                                                                                                                                                                                                                                                                               

Oral microbiome and pancreatic cancer summary
---------------------------------------------

Oral flora alterations exist in pancreatic cancer patients compared to healthy populations. Salivary RNA studies reveal *bacteroides* genus and *Granulicatella adiacens* are more common in pancreatic cancer patients than healthy subjects\[[@B12],[@B24]\]. However, *Neisseria elongata*, *Streptococcus mitis*, *Corynebacterium* genus, and the *Aggregatibacter* genus are present in lower concentrations in pancreatic cancer than healthy subjects\[[@B12],[@B24]\]. Combining salivary RNA biomarkers for *N. elongata* and *S. mitis* yielded an ROC-plot AUC value of 0.90 with 96.4% sensitivity and 82.1% specificity in distinguishing patients with pancreatic cancer from healthy subjects\[[@B12]\]. A cross-sectional study\[[@B25]\] identified of a significantly higher *Leptotrichia* and lower *Porphyromonas* colonization in pancreatic cancer patient saliva, translating to an *Leptotrichia:Porphyromonas* (L:P) ratio of biomarker significance. In this same study, a patient classified with an unknown digestive disease presented with an elevated L:P ratio that led to dedicated workup revealing a new diagnosis of pancreatic cancer\[[@B25]\]. Pilot successes deserve further exploration into utilizing salivary markers as potentially valuable non-invasive, economical screening strategies.

Interestingly, the highest concentration of plasma antibodies *to Porphyromonas gingivalis* (strain ATTC 53978), a pathogenic bacteria associated with periodontal disease, was linked with a 2-fold increased risk of pancreatic cancer\[[@B18]\]. The association was amplified over time, with the addition of 5 or 7 year lag\[[@B18]\]. Similar to case control studies of saliva samples revealing oral pathogens, *P. gingivalis* and *A*. *actinomycetemcomitans* are associated with increased risk for subsequent development of pancreatic cancer\[[@B26]\]. This finding is consistent with epidemiologic data that periodontal disease is an independent risk factor for pancreatic cancer development\[[@B20],[@B23],[@B27]\]. Alternatively, high antibody titers against non-pathogenic, commensal bacteria were associated with 45% decreased risk of pancreatic cancer compared to those with a lower antibody level profile\[[@B18]\]. Similarly *Fusobacterium* and *Lepotrichia* are protective and decreases risk, also in a dose dependent relationship\[[@B26]\]. *Lactobacillus* is a commensal oral cavity bacterium that diminishes gingival inflammation and cariogenic periodontal pathogenic bacteria\[[@B28]\]. Thus, with the clearly established role of periodontal disease and associated periodontal pathogens for pancreatic cancer risk profiles, any measures to prevent periodontal pathogens may serve protective role to prevent pancreatic cancer, but has not been studied on this topic specifically.

H. pylori and pancreatic cancer
-------------------------------

There is literature that illustrates a paradoxical nature of microorganisms relative to by site and tumor studied. For example, eradication of *H. pylori* causes regression of MALT lymphoma and decreases risk of metachronous gastric carcinoma after endoscopic resection for early stage gastric cancer\[[@B1],[@B29]\]. However, *H. pylori* gastric colonization decreases the risk of oesophageal adenocarcinoma that does not involve the gastric cardia\[[@B30]\]. *H. pylori* is a diverse bacteria with several virulent strain variations. Among the best studied are *Cytotoxin-associated gene A* (*Cag-A*) positive strains that express Cag-A virulence factor, which is linked to gastric inflammation, ulceration, and promoting malignant transformation in gastric cancer\[[@B31],[@B32]\]. *H. pylori* and *Cag-A* dominate microbiome studies in pancreatic cancer. Study results are variable and complex, as is noted in Table [2](#T2){ref-type="table"}\[[@B9]-[@B11],[@B33]-[@B42]\].

###### 

*Helicobacter pylori* and pancreatic cancer

  **Ref**.                                            **Study Design**                             **Case No**.   **Control No**.   **Detection**                                                       **Bacteria association**                                              **Outcome**                                   **Author conclusion**
  --------------------------------------------------- -------------------------------------------- -------------- ----------------- ------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Raderer et al\[[@B33]\], 1998, Austria              Case-control                                 92             27                Plasma IgG ELISA                                                    *H. pylori*                                                           OR = 2.1                                      *H. pylori* seropositivity prominent in pancreatic cancer patients compared with colorectal cancer combined with normal controls
  95%CI: 1.1-4.1                                                                                                                                                                                                                                                                                                            
  *P* = 0.035                                                                                                                                                                                                                                                                                                               
  Stolzenberg-Solomon et al\[[@B34]\] 2001, Finland   Nested case-control                          121            226               Plasma IgG ELISA                                                    cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori*                                   Male smokers seropositive for *H. pylori* were nearly twice as likely to develop pancreatic cancer compared to seronegative. Stronger influence adjusting for years of smoking
  OR = 1.87;                                                                                                                                                                                                                                                                                                                
  95%CI: 1.05-3.34                                                                                                                                                                                                                                                                                                          
  CagA+ strains                                                                                                                                                                                                                                                                                                             
  OR = 2.01;                                                                                                                                                                                                                                                                                                                
  95%CI: 1.09-3.70                                                                                                                                                                                                                                                                                                          
  de Martel et al\[[@B35]\], 2008, United States      Nested Case-control                          104            262               Plasma IgG ELISA                                                    cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori*                                   *H. pylori* infection is not associated with development of pancreatic cancer
  OR = 0.85;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.49-1.48                                                                                                                                                                                                                                                                                                          
  CagA+                                                                                                                                                                                                                                                                                                                     
  OR = 0.96;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.48-1.92                                                                                                                                                                                                                                                                                                          
  Lindkvist et al\[[@B36]\], 2008, Sweden             Nested Case-control                          87             263               Plasma IgG ELISA                                                    *H. pylori*                                                           *H. pylori* overall                           Adjusted risk for development of pancreatic cancer highly increased in never-smokers seropositive for *H. pylori*
  OR = 1.25                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.75-2.09                                                                                                                                                                                                                                                                                                          
  *H. pylori* in Never smokers                                                                                                                                                                                                                                                                                              
  AOR = 3.81                                                                                                                                                                                                                                                                                                                
  95%CI: 1.06-13.63                                                                                                                                                                                                                                                                                                         
  Risch et al\[[@B37]\] 2010, United States           Case-control                                 373            690               Plasma IgG ELISA                                                    cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   CagA negative *H. pylori* non-O blood group   CagA-negative *H. pylori* seropositivity is a risk factor for pancreatic cancer among individuals with non--O blood type
  OR = 2.78,                                                                                                                                                                                                                                                                                                                
  95%CI: 1.49-5.20,                                                                                                                                                                                                                                                                                                         
  *P* = 0.0014;                                                                                                                                                                                                                                                                                                             
  CagA negative *H. pylori* O-blood group                                                                                                                                                                                                                                                                                   
  OR = 1.28,                                                                                                                                                                                                                                                                                                                
  95%CI: 0.62-2.64,                                                                                                                                                                                                                                                                                                         
  *P* = 0.51                                                                                                                                                                                                                                                                                                                
  Trikudanathan et al\[[@B11]\], 2011                 Meta-analysis                                822            1513              meta-analysis of 6 case control studies                             *H. pylori*                                                           AOR = 1.38,                                   Significant positive association between the presence of *H. pylori* infection and pancreatic cancer.
  95%CI: 1.08-1.75                                                                                                                                                                                                                                                                                                          
  Gawin et al\[[@B38]\], 2012, Poland                 Case-control                                 139            177               Plasma IGg, ELISA, western blot                                     cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori*                                   No association between seropositivity of *H. pylori* or CagA with development of pancreatic cancer
  OR = 1.27;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.64-2.61                                                                                                                                                                                                                                                                                                          
  *P* = 0.514                                                                                                                                                                                                                                                                                                               
  CagA+                                                                                                                                                                                                                                                                                                                     
  OR = 0.90;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.46-1.73,                                                                                                                                                                                                                                                                                                         
  *P* = 0.744                                                                                                                                                                                                                                                                                                               
  Xiao et al\[[@B39]\], 2013                          Meta-analysis                                1083           1950              meta-analysis of 9 case-control studies                             cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori* Overall                           Borderline positive association *H. pylori* seropositivity overall. Adjusted risk for high quality studies revealed a significant, but modest association. CagA virulence seropositivity was not associated with pancreatic cancer
  OR = 1.47                                                                                                                                                                                                                                                                                                                 
  95%CI: 1.22-1.77                                                                                                                                                                                                                                                                                                          
  Adjusted for "High quality" studies                                                                                                                                                                                                                                                                                       
  AOR = 1.28;                                                                                                                                                                                                                                                                                                               
  95%CI: 1.01-1.63                                                                                                                                                                                                                                                                                                          
  Adjusted for CagA positive                                                                                                                                                                                                                                                                                                
  AOR = 1.47;                                                                                                                                                                                                                                                                                                               
  95%CI: 0.79-2.57                                                                                                                                                                                                                                                                                                          
  Yu et al\[[@B40]\], 2013, Finland                   Case-control                                 353            353               multiplex serology to 4 *H. pylori* antigens                        *H. pylori*                                                           OR = 0.85;                                    No association between seropositivity of *H. pylori* with development of pancreatic cancer
  95%CI: 0.49 -1.49                                                                                                                                                                                                                                                                                                         
  Wang et al\[[@B41]\], 2014                          Meta-analysis                                2049           2861              Meta-analysis of 9 case-control studies (2 non- English language)   cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori* overall                           Eastern Asian populations demonstrate significant decreased risk pancreatic cancer associated with *H. pylori* seropositivity. No association present in Western populations
  OR = 1.06,                                                                                                                                                                                                                                                                                                                
  95%CI: 0.74-1.37                                                                                                                                                                                                                                                                                                          
  Eastern Asian Population                                                                                                                                                                                                                                                                                                  
  *H. pylori*                                                                                                                                                                                                                                                                                                               
  OR = 0.62,                                                                                                                                                                                                                                                                                                                
  95%CI: 0.49-0.76                                                                                                                                                                                                                                                                                                          
  Cag-A positive                                                                                                                                                                                                                                                                                                            
  OR = 0.66,                                                                                                                                                                                                                                                                                                                
  95%CI: 0.52-0.80                                                                                                                                                                                                                                                                                                          
  Western European population                                                                                                                                                                                                                                                                                               
  *H. pylori*                                                                                                                                                                                                                                                                                                               
  OR = 1.14                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.89-1.40                                                                                                                                                                                                                                                                                                          
  Cag-A positive                                                                                                                                                                                                                                                                                                            
  OR = 0.84                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.63-1.04                                                                                                                                                                                                                                                                                                          
  Risch et al\[[@B42]\], 2014, Shanghai               Case-control                                 761            794               Plasma IGg, ELISA                                                   cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   Cag-A positive *H. pylori*                    Decreased pancreas-cancer risk was seen for CagA positive *H. pylori* compared to seronegativity for both *H. pylori* and CagA. A modest increased risk for CagA-negative *H. pylori* seropositivity
  AOR = 0.68;                                                                                                                                                                                                                                                                                                               
  95%CI: 0.54-0.84                                                                                                                                                                                                                                                                                                          
  Cag-A negative *H. pylori*                                                                                                                                                                                                                                                                                                
  AOR = 1.28;                                                                                                                                                                                                                                                                                                               
  95%CI: 0.76-2.13                                                                                                                                                                                                                                                                                                          
  Chen et al\[[@B9]\], 2015                           Meta-analysis                                1446           2236              meta-analysis of 5 case control studies                             cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   Overall                                       CagA-negative, nonvirulent strains of *H. pylori* may be a risk factor for pancreatic cancer. No association with seropositivity for *H. pylori* infection overall, nor when adjusted for CagA or virulent strain infection
  OR = 0.99;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.65-1.50                                                                                                                                                                                                                                                                                                          
  CagA+                                                                                                                                                                                                                                                                                                                     
  OR = 0.92;                                                                                                                                                                                                                                                                                                                
  95%CI: 0.65 -1.3                                                                                                                                                                                                                                                                                                          
  Virulent strain infection                                                                                                                                                                                                                                                                                                 
  OR = 0.97                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.50-1.89                                                                                                                                                                                                                                                                                                          
  Nonvirulent infection                                                                                                                                                                                                                                                                                                     
  OR = 1.47                                                                                                                                                                                                                                                                                                                 
  95%CI: 1.11-1.96                                                                                                                                                                                                                                                                                                          
  Schulte et al\[[@B10]\], 2015                       Combination Case-control and meta-analysis   580            626               Plasma IGg, ELISA and meta-analysis of 10 case-control studies      cytotoxin-associated gene-A (CagA) virulence factor and *H. pylori*   *H. pylori* overall                           No overall association observed for *H. pylori* seropositivity and risk of pancreatic cancer, but evidence of non-significant CagA strain-specific associations
  OR = 1.00                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.74-1.35                                                                                                                                                                                                                                                                                                          
  Cag-A negative                                                                                                                                                                                                                                                                                                            
  AOR = 1.23                                                                                                                                                                                                                                                                                                                
  95%CI: 0.83-1.82                                                                                                                                                                                                                                                                                                          
  Cag-A positive                                                                                                                                                                                                                                                                                                            
  OR = 0.74                                                                                                                                                                                                                                                                                                                 
  95%CI: 0.48-1.15                                                                                                                                                                                                                                                                                                          

H. pylori and pancreatic cancer summary
---------------------------------------

Results from *H. pylori* case studies in pancreatic cancer reveals complex mixed results pending virulence strain *cag-A* status. Consensus from recent meta-analysis is that there is a modestly significant increased risk associated with development of pancreatic cancer for *cag-A*-negative *H. pylori* strain\[[@B9]-[@B11],[@B39]\], with positive correlated adjustment factors including non-O blood type\[[@B37],[@B43]\] and active smoking status\[[@B34],[@B36]\]. The general literature trend summarized in Table [2](#T2){ref-type="table"} is *cag-A*-positive strains results in decreased risk or non-significant association with pancreatic cancer. Notable global population differences exist as the majority of studies highlighted in this review are mainly relevant to Western European or North American ethnic groups. The results of one meta-analysis addressing global studies\[[@B41]\] and pancreatic cancer risk including two Eastern Asian population case-cohorts that suggest a decreased risk of pancreatic cancer risk for *H. pylori* seropositivity overall, including *Cag-A*-positive strains in Eastern Asian ethnic region\[[@B41]\].

Tissue microbiome and pancreatic cancer
---------------------------------------

We found three human pancreatic adenocarcinoma tissue studies dedicated to microbiome alterations or their effect on the tumor microenvironment (Table [3](#T3){ref-type="table"}\[[@B44]-[@B46]\]).

###### 

Tissue microbiome and pancreatic cancer

  **Ref**.                                                       **Study design**   **Case sample size**   **Detection method and sample**                  **Bacteria association**   **Outcome**                                                                                                                                                   **Author conclusion**
  -------------------------------------------------------------- ------------------ ---------------------- ------------------------------------------------ -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Nilsson et al\[[@B44]\], 2006, Sweden                          Case-control       84                     DNA genus specific PCR, surgical specimen        *H. pylori*                *Helicobacter* DNA detected in pancreas of 75% patients with adenocarcinoma, but not detected in any control                                                  *Helicobacter* DNA, mostly *H. pylori* genus, commonly detected in pancreatic cancer
  Takayama et al\[[@B45]\], 2007, Japan                          Abstract           \-                     ELISA and western blot, Pre-clinical cell line   *H. pylori*                IL-8 and VEGF secretion and proliferation factors NF-kappa-B, AP-1, and serum response element of human pancreatic cells increased by *H. pylori* infection   *H. pylori* infection of human pancreatic cells may increase malignant potential of pancreatic cells
  Mitsuhashi et al\[[@B46]\], 2015, Japan                        Case-control       283                    PCR, surgical specimen                           Fusobacterium              Detected in 8.8% cases.                                                                                                                                       significantly shorter survival observed in the *Fusobacterium* species-positive group
  Median cancer-survival (mo) positive *vs* negative detection                                                                                                                                                                                                                                                                                       
  17.2 *vs* 32.5 for                                                                                                                                                                                                                                                                                                                                 
  log-rank *P* = 0.021                                                                                                                                                                                                                                                                                                                               

Tissue microbiome and pancreatic cancer summary
-----------------------------------------------

In one case control study, enteric strains of *Helicobacter* DNA were demonstrated to colonize the pancreas in 75% of adenocarcinoma patients but not in pancreatic controls with benign disease\[[@B44]\]. Among proposed mechanisms for dissemination may result from hepatobiliary translocation or hematogenous seeding\[[@B44],[@B46]\]. However, DNA of different *Helicobacter* species is mutually exclusive by sampled site\[[@B44]\]. For example, *Helicobacter* identified in the pancreas compared with *Helicobacter* of gastroduodenal tissue of the same patient were different *Helicobacter* subspecies\[[@B44]\]. Thus, dissemination of *H. pylori* from the stomach to the pancreas is unlikely, instead a subspecies tissue tropism may exist\[[@B44]\].

Both direct microbe colonization and downstream proliferative metabolic affects may promote tumor-associated inflammation preserved by low-grade chronic inflammation\[[@B6],[@B29],[@B47]\] . Evidence of this effect in a pre-clinical study of human a pancreatic cell line showed *H. pylori* colonization of a human pancreatic cell line expressed increased factors for malignant potential including proliferative factors, NF-kappa-B, activator protein-1, proflammatory IL-8 activity, vascular endothelial growth factor secretion, and the growth factor promoter, serum response element\[[@B45]\]. The overall result is activation of molecular pathways for tumor growth and progression in the setting of *H. pylori* infection\[[@B45]\].

*Fusobacterium* is an anaerobic, oral bacterium that has been identified in pancreatic abscesses and carries unfavorable prognostic implications in some gastrointestinal cancers\[[@B46]\]. To explore a role for *Fusobacterium* in pancreatic cancer, surgical specimens of pancreatic adenocarcinoma were analyzed for presence of this bacterium. Only 8% of specimens in this cohort contained *Fusobacterium* colonization\[[@B46]\]. However, pancreatic ductal adenocarcinoma surgical specimens with presence of *Fusobacterium* colonization was identified as an independent predictive factor for shorter survival compared to *Fusobacterium* negative tumors\[[@B46]\]. The *fusobacterium* positive sample group also demonstrated 28% detection of paired normal tissue\[[@B46]\]. The presence of *Fusobacterium* in normal tissue margin suggests it may contribute to malignant potential, but this theory requires further exploration\[[@B46]\].

DISCUSSION
==========

The oral microbiome has a protective role against pancreatic cancer in a healthy, commensal state, but may promote malignancy in a pathologic state\[[@B1],[@B2],[@B4]-[@B6],[@B12],[@B18],[@B24],[@B25]\]. Shifts in taxa dominance and diversity of oral bacterial communities, especially those reflective of periodontal disease are associated with increased pancreatic cancer risk\[[@B12],[@B18],[@B24],[@B25]\]. This correlates clinically with periodontal disease status, a validated independent risk factor for development of pancreatic cancer\[[@B21]-[@B23]\]. Bacterial markers of periodontal disease\[[@B18]\] and shifts in microbial taxa diversity\[[@B12],[@B24],[@B25]\] have promising potential to serve as non-invasive screening biomarkers of pancreatic cancer. The evidence is strong enough to warrant targeted risk reduction strategies in patient education and modifiable lifestyle counseling regarding maintenance of oral hygiene.

A directly carcinogenic role for *H. pylori* has been explored after discovering enteric strains of *Helicobacter* DNA demonstrated to colonize the pancreas in a majority of sampled pancreatic adenocarcinoma but not in patients with benign disease\[[@B44]\]. A preclinical study\[[@B45]\] examined direct *H. pylori* colonization and associated activation of molecular pathways for tumor growth and progression\[[@B45]\]. These downstream molecular effects highlight oncogenic potential with microbiome influence that promotes tumor-associated inflammation preserved by low-grade chronic inflammation\[[@B6],[@B29],[@B47]\]. Despite the existence of several proposed carcinogenic mechanisms of dysbiosis, inflammation is a central facilitator illustrated in pancreatic cancer murine models, human cell lines, and tumor translational expression profiles\[[@B6]\].

Future directions
-----------------

There have been studies that indicate the microbiome and antibiotics modulate tumor response to chemotherapy\[[@B48],[@B49]\]. Germ-free and antibiotic treated murine models highlight the protective effect of commensal bacteria by shaping the inflammatory network required for favorable response to anti-tumor therapy\[[@B48]\]. In murine models, platinum therapy eliminated most subcutaneous lymphoma tumors and prolonged survival in control mice\[[@B48]\]. However, antibiotic-treated and germ free mice failed to respond to platinum-treatment, in part by decreasing reactive oxygen species\[[@B48]\]. Similarly, CTLA-4 inhibitor treated murine models with sarcoma suggest that gut microbiota, specifically *bacteroides* subspecies, are required for the successful anti-tumor effects of CTLA-4 blockade\[[@B49]\]. Notably, antibiotic and germ free mice with sarcomas do not respond to CTLA-4 inhibitor at baseline, but recover antitumor activity with recolonization of gut commensals by human fecal microbiota transplantation of specific *bacteroides* subspecies\[[@B49]\]. Oral administration of *Bifidobacterium* in murine models with melanoma augments the immune response to tumor cells, in part by dendritic cell activation of the innate immune system\[[@B49]\]. This effect was not observed with administration of *lactobacillus* species, suggesting a complex, species specific modulation of the immune system *in vivo*\[[@B49]\]. The potential to utilize probiotics in humans to amplify antitumor response to existing chemotherapy and immunotherapy protocols requires further investigation\[[@B50]\].

Anti-tumor therapy and commensal flora collaborate in part, by loss of TNF-dependent early tumor necrosis response, down-regulation of inflammatory cytokines, phagocytosis, antigen presentation, and adaptive immune response gene expression controlling tissue development and cancer\[[@B48]\]. The loss of commensal organisms by antibiotics and the possibility of carcinogenic promoting effects of antibiotics have been explored. The risk related to pancreatic cancer seems limited to the penicillin class, especially with more than five courses, but this risk diminishes over time\[[@B51]\]. Macrolides, cephalosporins, tetracyclines, antivirals, and antifungals were not associated with increased risk of pancreatic cancer\[[@B51]\]. The impact of antibiotics on commensal framework may explain the need for repeated antibiotic exposures, leading to an enduring change in bacterial community diversity\[[@B51]\]. Murine models demonstrate *lactobacillus* was among quickest flora to recover in the gut after antibiotic therapy. However, the effect of antibiotics on the gut microbiome is enduring at four weeks after exposure; the population is deficient, and not reflective of its healthy, baseline, pre-antibiotic diversity\[[@B48]\].

Commensal bacteria offer protection from disease by inflammatory-modulating activity as above, but also by hormonal homeostasis, detoxification, and metabolic effects of bacterial metabolites. For example, murine models show *lactobacilli* are consistently reduced in cachectic mouse models\[[@B52]\]. A *lactobacilli* cocktail combination with prebiotic substrate that supports growth of microorganisms, changes the dysbiotic populations of cecal microbiota composition in murine models, clinically resulting in improved survival and reduction of cachexia\[[@B53]\]. These are highly important implications in pancreatic adenocarcinoma population since these patients carry the strongest burden of cancer cachexia among all malignancies, present in up to 80% of patients\[[@B54],[@B55]\] resulting in reduced survival and progressive disease\[[@B55]-[@B57]\]. Weight stabilization alone significantly proven to improve survival in pancreatic adenocarcinoma patients with unresectable disease\[[@B58]\].

In conclusion, the initial motive to explore microbiome role in carcinogenesis may lead to identifying reliable non-invasive screening strategies and discern additional modifiable risk factors. With further investigation, potentially microbiome studies in pancreatic cancer could offer therapeutic targets. Perhaps the most extraordinary opportunity is to favorably transform cancer response to existing treatment protocols and improve survival by reduction of cancer-related cachexia by manipulating human gut microbiota.

COMMENTS
========

Background
----------

Recently, there are literature reports on influences of microbiome alteration contributing to carcinogenesis of multiple malignancies. Among the most controversial is dysbiosis related to pancreatic cancer. Pancreatic cancer often denotes a poor clinical prognosis in part due to late recognition and treatment resistance, warranting investigations for modifiable risk factors, early screening biomarkers, and microenvironment elements that affect patient outcomes.

Research frontiers
------------------

Murine models demonstrate commensal microbiome taxa modulates a favorable tumor response to chemotherapy in multiple tumor types In addition, manipulation of cecal microbiome composition with lactobacillus in murine models, have resulted in improved survival and reduction of cachexia a clinically significant burden in the majority of pancreatic cancer patients.

Innovations and breakthroughs
-----------------------------

This review article serves to update literature on microbiome alterations associated with pancreatic cancer, its potential utility as an early screening biomarker, examine the influence of the microbiome in antitumor therapy, and the potential impact of microbiome manipulation to affect pancreatic cancer patient outcomes.

Applications
------------

Exploring the microbiome role in carcinogenesis may lead to identifying reliable non-invasive screening strategies and discern additional modifiable risk factors. With further investigation, potentially microbiome studies in pancreatic cancer could offer therapeutic targets. Perhaps the most extraordinary opportunity is to favorably transform cancer response to existing treatment protocols and improve survival by reduction of cancer-related cachexia by manipulating human gut microbiota.

Peer-review
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This review describes the relationships between microbiome and pancreatic cancer. The data in this report is of considerable importance in investigations for modifiable risk factors of pancreatic cancer.
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